Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD4-targeted Tat mRNA-LNP
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CD4-targeted Tat mRNA-LNP is an experimental latency reversal agent (LRA) designed to reactivate the latent HIV reservoir in CD4+ T cells. The therapeutic consists of mRNA encoding the HIV-1 Tat (trans-activator of transcription) protein, encapsulated within lipid nanoparticles (LNPs) that are surface-functionalized to specifically target the CD4 receptor. Upon delivery and translation, the Tat protein translocates to the nucleus and binds to the HIV-1 long terminal repeat (LTR) promoter, potently inducing viral gene expression. This "shock" phase of the "shock and kill" strategy aims to make latently infected cells detectable by the immune system or susceptible to viral cytopathic effects. In preclinical studies, it has been evaluated in combination with other agents like romidepsin to enhance the reactivation of HIV gene expression in individuals on antiretroviral therapy (ART).
- Other names
- CD4-targeted Tat mRNA-LNPsCD-4-targeted Tat mRNA-LNPsCD 4-targeted Tat mRNA-LNPs
02
Targets
CD4 (T lymphocyte surface antigen)Human immunodeficiency virus type 1 long terminal repeat promoter / trans-activation response element transcriptional axis (HIV-1 LTR/TAR axis)
Beyond the preview
Go deeper on CD4-targeted Tat mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD4-targeted Tat mRNA-LNP.